Leucovorin /m^2

Phase 3Small molecule

Roche

Leucovorin /m^2 is one of 65 small molecule programs targeting Adenocarcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AdenocarcinomaActive, not recruiting

Metastatic Colorectal CancerActive, not recruiting

AdenocarcinomaPhase 2

Active, not recruiting

Metastatic Colorectal CancerPhase 3

Active, not recruiting

Competition

Competitive Landscape

698 competitors in Metastatic Colorectal Cancer

#DrugCompanyPhaseTrials

Lumakras

Amgen

Phase 3

2 2

Lynparza

AstraZeneca

Phase 3

2 3

Azulfidine

Pfizer

Phase 3

1 4

Theraplaza

BBiotech Pharmaceutical Co., Ltd.

Phase 3

2 5

Cecon

MMcGuff Pharmaceuticals, Inc.

Phase 3

1 6

Cosela

PPharmacosmos A/S

Phase 3

1 7

Investigator's Choice Chemotherapy

Genmab

Phase 3

1 8

HX008

BBinhui Biopharmaceutical Co., Ltd.

Phase 3

1 9

QL1706

Qilu Pharmaceutical Co., Ltd.

Phase 3

1 10

Brivanib Alaninate

GGynecologic Oncology Group

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Metastatic Colorectal Cancer1 trial

A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer

Completed· Roche logo

Roche·Phase 3·NCT00069095·2,035 enrolled

Adenocarcinoma1 trial

FOLFOX-A in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma

Completed·—·Phase 2·NCT03283761·39 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Leucovorin /m^2. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Leucovorin /m^2 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Leucovorin /m^2. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Roche

Leucovorin /m^2

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Metastatic Colorectal Cancer1 trial

Adenocarcinoma1 trial

References

Drug Info

Quick Facts

Related News